Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $13.0952W HIGH $19.85
Volume
1.61 M
Value Traded
62.01 M
Short % Float
4.39%
-1.21%Week
-3.71%1 Month
-2.66%3 Month
+17.15%6 Month
-34.37%5 Year
-42%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
5.11 B
EPS (TTM)
0.57
P/E Ratio
31.24
Ent. Value
6.90 B
Total Shares
285.20 M
Float Shares
279.37 M
Insiders
2.10%
Institutions
103.26%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
SHC Catalyst Timeline
Dated clinical, regulatory and corporate events for Sotera Health Company
Past FDA Catalysts and PDUFA Decisions
How SHC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Sotera Health Company is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every SHC program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Petras Michael B. Jr.Director, Officer (Executive Chairman) | Sell | -294,515 397,912 held | $18.50 | 08/17/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SHC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Avidity Partners | 1.5 % (7.1 %) | 69.71 M | 2.96 M | 24.47% ( 582.00 K) |
SHC Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SHC ranks across every disease it competes in
Competitive Position is a premium feature
See how SHC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSHC News
SHC▲ +5.2%on this news
Sotera Health Delivers Strong Second-Quarter and First-Half 2026 Results and Raises FY 2026 Outlook
Sotera Health Company reported robust financial results for Q2 and the first half of 2026, with net revenues up 9.2% and net income significantly increasing to $54 million. The company also raised its full-year outlook for both revenue and adjusted EBITDA growth, reflecting strong performance across its business segments. CEO Alton Shader expressed confidence in the company's growth strategy and customer relationships.
Read more →SHCSotera Health Announces Second-Quarter 2026 Earnings Release Date
Sotera Health Company has announced the release date for its second-quarter 2026 earnings, set for August 6, 2026. The financial results will be available before market opening, followed by a conference call at 9:00 a.m. EDT. Investors can access a live webcast of the call and find updates on the company's website.
Read more →SHCSotera Health Announces Secondary Offering of Common Stock
Sotera Health Company has announced a secondary offering of 31,838,253 shares of common stock, which are being sold by affiliates of Warburg Pincus LLC and GTCR LLC. The company itself will not be selling any shares or receiving any proceeds from this offering, as it will only cover associated expenses. Goldman Sachs & Co. LLC is serving as the underwriter for this transaction. The announcement emphasizes potential risks related to the offering that could affect shareholder value.
Read more →SHCSotera Health Delivers Strong First-Quarter 2026 Results and Reaffirms 2026 Outlook
Sotera Health reported a strong financial performance for Q1 2026, with net revenues increasing by 10% year-over-year. The company achieved a net income of $27 million, a significant improvement from a loss in Q1 2025. Adjusted EBITDA also saw a 10.5% increase, and the company reaffirmed its full-year growth outlook. The positive results were driven by strong performance in its Sterigenics and Nordion segments.
Read more →SHCSotera Health Announces Leadership Transition
Sotera Health announced a leadership transition with Alton Shader set to become CEO on May 26, 2026, succeeding Michael B. Petras, Jr. Petras will assume the role of Executive Chairman and continue to guide the company. Shader, with extensive experience in the medical industry, aims to build on Sotera's success in providing critical healthcare services.
Read more →SHCSotera Health Announces First-Quarter 2026 Earnings Release Date
Sotera Health Company has announced that it will release its financial results for the first quarter of 2026 before the market opens on May 5, 2026. Following the announcement, management will conduct a conference call to discuss the operating and financial results at 9:00 a.m. EDT. The company continues to emphasize its commitment to providing essential sterilization solutions and advisory services to the healthcare sector.
Read more →SHCSotera Health Appoints Kenneth D. Krause to the Board of Directors
Sotera Health Company has appointed Kenneth D. Krause as an independent director to its Board of Directors, effective March 16, 2026. Krause brings over ten years of experience as a public company CFO and a strong background in strategy and financial governance. He will serve on the Audit and Litigation Committees. Additionally, Dean S. Mihas has resigned from the Board due to a reduction in the number of directors designated by certain stockholders, ending his service since October 2020.
Read more →SHCSotera Health Delivers 20th Consecutive Year of Revenue Growth and Provides 2026 Outlook
Sotera Health Company reported a 4.6% increase in fourth-quarter 2025 net revenues, marking its 20th consecutive year of revenue growth. The company achieved a net income of $35 million for the quarter and $78 million for the full year, driven by strong demand for its sterilization and lab testing services. Looking ahead, Sotera Health is optimistic about its financial outlook for 2026.
Read more →SHCSotera Health Announces Fourth-Quarter and Full-Year 2025 Earnings Release Date
Sotera Health Company has announced the release date for its fourth-quarter and full-year 2025 earnings. The financial results will be available before the market opens on February 24, 2026, followed by a conference call at 9:00 a.m. ET to discuss the results. The event will be accessible via a live webcast.
Read more →SHCSotera Health Appoints Richard Kyle to the Board of Directors
Sotera Health has appointed Richard G. Kyle as an independent director on its Board of Directors. Kyle, who previously served as CEO of The Timken Company, brings extensive experience in global operations and financial management. He will also participate in the Leadership Development and Compensation Committee and the Nominating and Corporate Governance Committee.
Read more →SHCSotera Health to Showcase Continued Revenue Growth and Strategic Value Creation at 44th Annual J.P. Morgan Healthcare Conference
Sotera Health Company (SHC) has announced its continued revenue growth trajectory at the 44th Annual J.P. Morgan Healthcare Conference, projecting revenue to exceed $1.16 billion for 2025, marking at least a 5.5% increase year over year. The company's Chairman and CEO emphasized their strong business model and commitment to customer excellence, reflecting two decades of revenue growth. Full-year financial results and outlook for 2026 will be shared on February 24, 2026. Sotera Health operates through three key businesses: Sterigenics, Nordion, and Nelson Labs.
Read more →SHCSotera Health to Present at the 44th Annual J.P. Morgan Healthcare Conference
Sotera Health Company announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, scheduled for January 12, 2026. The company's management will present at 1:30 p.m. ET and will also hold investor meetings. A live webcast of the presentation will be available on their website, with a replay accessible within 48 hours.
Read more →SHCSotera Health Reports Strong Third-Quarter and Year-to-Date 2025 Results
Sotera Health Company reported robust financial results for Q3 and year-to-date 2025, with net revenues rising by 9.1% to $311 million and net income increasing significantly. The company achieved double-digit growth in Adjusted EBITDA and reaffirmed its revenue outlook for the year while raising its Adjusted EBITDA forecast. However, pending settlements related to ethylene oxide claims pose potential risks.
Read more →SHCSotera Health Announces Third-Quarter 2025 Earnings Release Date
Sotera Health Company has announced the date for its third-quarter 2025 earnings release, scheduled for November 4, 2025. The company will provide financial results for the quarter ended September 30, 2025, before the market opens. Following the release, a conference call will be held to discuss the results and highlights.
Read more →SHC▲ +24.5%on this news· ran to +40% by day 3
Sotera Health Reports Strong Second-Quarter and First-Half 2025 Results
Sotera Health Company (SHC) reported strong financial results for the second quarter and first half of 2025, with a 6.4% rise in net revenues to $294 million and a notable increase in Adjusted EBITDA by nearly 10%. Despite a decrease in net income due to ongoing ethylene oxide claims settlements, the company raised its full-year outlook for revenue and Adjusted EBITDA, indicating a positive trend in performance. The company highlighted robust growth driven by Sterigenics, although some challenges were noted in the Nordion and Nelson Labs segments.
Read more →SHCSotera Health Announces Second-Quarter 2025 Earnings Release Date
Sotera Health Company announced that it will release its financial results for the second quarter of 2025 on August 8, 2025. Following the earnings release, management will host a conference call at 9:00 a.m. EDT to discuss the results and operating highlights. Investors can participate by phone or access a live webcast via the company's website, with a replay available later that day.
Read more →About Sotera Health Company
Headquarters9100 SOUTH HILLS BLVD, SUITE 300, BROADVIEW HEIGHTS, OH, 44147
BIOPHARMAWATCH ELITE PLUS
Trade the next SHC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime